We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
If You Invested $1000 in Boston Scientific 10 Years Ago, This Is How Much You'd Have Now
Read MoreHide Full Article
How much a stock's price changes over time is important for most investors, since price performance can both impact your investment portfolio and help you compare investment results across sectors and industries.
The fear of missing out, or FOMO, also plays a factor in investing, especially with particular tech giants, as well as popular consumer-facing stocks.
What if you'd invested in Boston Scientific (BSX - Free Report) ten years ago? It may not have been easy to hold on to BSX for all that time, but if you did, how much would your investment be worth today?
Boston Scientific's Business In-Depth
With that in mind, let's take a look at Boston Scientific's main business drivers.
Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success.
Boston Scientific reorganized its operational structure and aggregated its core businesses, each of which generates revenues from the sale of Medical Devices, into two reportable segments, MedSurg (35.8% of total revenue; 2024 organic growth was 7.5% over 2023) and Cardiovascular (accounting for the rest; 21.9% organic growth in 2024).
The Cardiovascular segment coprises Cardiology division (represents the combined former Rhythm Management and Interventional Cardiology businesses) and Peripheral Interventions.
MedSurg group comprises 3 sub segments, viz. Endoscopy; Urology; and Neuromodulation.
The company is one of the leading players in the interventional cardiology market with its coronary stent product offerings. Boston Scientific markets a broad portfolio of internally-developed and self-manufactured drug eluting stents including the Promus PREMIER, Promus Element and Promus Element Plus everolimus-eluting stents. In addition, in Europe, it markets the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System featuring an ultra-thin abluminal (outer) bioabsorbable polymer coating.
The company also markets balloon catheters, rotational atherectomy systems, guide wires, guide catheters, embolic protection devices, and diagnostic catheters used in percutaneous transluminal coronary angioplasty (PTCA) procedures, as well as intravascular ultrasound (IVUS) imaging systems.
Bottom Line
Anyone can invest, but building a successful investment portfolio requires research, patience, and a little bit of risk. So, if you had invested in Boston Scientific, ten years ago, you're likely feeling pretty good about your investment today.
According to our calculations, a $1000 investment made in January 2016 would be worth $5,432.78, or a gain of 443.28%, as of January 7, 2026, and this return excludes dividends but includes price increases.
The S&P 500 rose 248.94% and the price of gold increased 289.24% over the same time frame in comparison.
Analysts are anticipating more upside for BSX.
Despite macroeconomic issues, primarily tariff tensions and related cost inflation, Boston Scientific is seeing strength across its target markets. Strong demand for its MedSurg and Cardiovascular lines, traction in the United States and internationally, supported by launches of next-generation devices such as the WATCHMAN FLX Pro (approved in China) and the FARAPULSE PFA System, are important drivers. Contributions from accretive acquisitions (newer being Elutia) further complement the growth trajectory. The Pain and Brain franchises are gaining solid traction in 2025 supported by momentum in Intracept and the Cartesia X/HX leads. The 2025 organic growth guidance of 15.5 % builds confidence in the stock. On the flip side, mounting costs remain a concern. Tariffs continue to impact margins and FX exposure remains a structural risk.
Over the past four weeks, shares have rallied 5.68%, and there have been 1 higher earnings estimate revisions in the past two months for fiscal 2025 compared to none lower. The consensus estimate has moved up as well.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
If You Invested $1000 in Boston Scientific 10 Years Ago, This Is How Much You'd Have Now
How much a stock's price changes over time is important for most investors, since price performance can both impact your investment portfolio and help you compare investment results across sectors and industries.
The fear of missing out, or FOMO, also plays a factor in investing, especially with particular tech giants, as well as popular consumer-facing stocks.
What if you'd invested in Boston Scientific (BSX - Free Report) ten years ago? It may not have been easy to hold on to BSX for all that time, but if you did, how much would your investment be worth today?
Boston Scientific's Business In-Depth
With that in mind, let's take a look at Boston Scientific's main business drivers.
Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success.
Boston Scientific reorganized its operational structure and aggregated its core businesses, each of which generates revenues from the sale of Medical Devices, into two reportable segments, MedSurg (35.8% of total revenue; 2024 organic growth was 7.5% over 2023) and Cardiovascular (accounting for the rest; 21.9% organic growth in 2024).
The Cardiovascular segment coprises Cardiology division (represents the combined former Rhythm Management and Interventional Cardiology businesses) and Peripheral Interventions.
MedSurg group comprises 3 sub segments, viz. Endoscopy; Urology; and Neuromodulation.
The company is one of the leading players in the interventional cardiology market with its coronary stent product offerings. Boston Scientific markets a broad portfolio of internally-developed and self-manufactured drug eluting stents including the Promus PREMIER, Promus Element and Promus Element Plus everolimus-eluting stents. In addition, in Europe, it markets the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System featuring an ultra-thin abluminal (outer) bioabsorbable polymer coating.
The company also markets balloon catheters, rotational atherectomy systems, guide wires, guide catheters, embolic protection devices, and diagnostic catheters used in percutaneous transluminal coronary angioplasty (PTCA) procedures, as well as intravascular ultrasound (IVUS) imaging systems.
Bottom Line
Anyone can invest, but building a successful investment portfolio requires research, patience, and a little bit of risk. So, if you had invested in Boston Scientific, ten years ago, you're likely feeling pretty good about your investment today.
According to our calculations, a $1000 investment made in January 2016 would be worth $5,432.78, or a gain of 443.28%, as of January 7, 2026, and this return excludes dividends but includes price increases.
The S&P 500 rose 248.94% and the price of gold increased 289.24% over the same time frame in comparison.
Analysts are anticipating more upside for BSX.
Despite macroeconomic issues, primarily tariff tensions and related cost inflation, Boston Scientific is seeing strength across its target markets. Strong demand for its MedSurg and Cardiovascular lines, traction in the United States and internationally, supported by launches of next-generation devices such as the WATCHMAN FLX Pro (approved in China) and the FARAPULSE PFA System, are important drivers. Contributions from accretive acquisitions (newer being Elutia) further complement the growth trajectory. The Pain and Brain franchises are gaining solid traction in 2025 supported by momentum in Intracept and the Cartesia X/HX leads. The 2025 organic growth guidance of 15.5 % builds confidence in the stock. On the flip side, mounting costs remain a concern. Tariffs continue to impact margins and FX exposure remains a structural risk.
Over the past four weeks, shares have rallied 5.68%, and there have been 1 higher earnings estimate revisions in the past two months for fiscal 2025 compared to none lower. The consensus estimate has moved up as well.